Get the Stockscreener App
0.8798
6.76%
0.0557
Iridex Corp stock is traded at $0.8798, with a volume of 155.30K.
It is up +6.76% in the last 24 hours and up +39.10% over the past month.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
See More
Previous Close:
$0.8241
Open:
$0.793
24h Volume:
155.30K
Relative Volume:
0.07
Market Cap:
$15.45M
Revenue:
$52.58M
Net Income/Loss:
$-3.28M
P/E Ratio:
-4.5656
EPS:
-0.1927
Net Cash Flow:
$-2.53M
1W Performance:
-2.03%
1M Performance:
+39.10%
6M Performance:
-15.40%
1Y Performance:
-17.00%
1-Day Range:
$0.77
$0.9031
1-Week Range:
$0.7834
$0.9805
52-Week Range:
$0.607
$1.6481
Iridex Corp Stock (IRIX) Company Profile
Name
Iridex Corp
Sector
Industry
Phone
(650) 940-4700
Address
1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA
Compare IRIX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
0.8798 | 15.45M | 52.58M | -3.28M | -2.53M | -0.1927 |
ABT
Abbott Laboratories
|
104.61 | 181.02B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.31 | 121.91B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
291.50 | 111.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.81 | 63.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.65 | 49.95B | 6.30B | 1.07B | 1.09B | 1.8406 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-17 | Resumed | ROTH Capital | Buy |
| Dec-21-16 | Initiated | ROTH Capital | Buy |
| Jan-26-16 | Initiated | Singular Research | Buy |
| Jan-03-07 | Initiated | First Albany | Buy |
Iridex Corp Stock (IRIX) Latest News
Form 4 IRIDEX Corporation: Patrick Mercer (Director, President and CEO) For: 1 October - Investing.com Canada
Iridex study shows two-year glaucoma treatment outcomes - Investing.com
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma - GlobeNewswire Inc.
A glaucoma laser treatment lowered eye pressure and medicine use over two years. - Stock Titan
Iridex Announces the Publication of Two-Year Independent - GlobeNewswire
Iridex director Lin Shih-Yao David buys $438,762 in stock By Investing.com - Investing.com Nigeria
Iridex director Lin Shih-Yao David buys $273,611 in company stock - Investing.com
Iridex director David Lin’s entity buys $597,902 in common stock - Investing.com
Iridex director Lin Shih-Yao David buys $438,762 in stock - Investing.com
Form 4 IRIDEX Corporation For: 7 October By Investing.com - Investing.com Nigeria
Form 4 IRIDEX Corporation For: 7 October By Investing.com - Investing.com India
One investor makes 30 open-market purchases of IRIDEX (IRIX) shares. - Stock Titan
Iridex Insider Bought Shares Worth $597,903, According to a Recent SEC Filing - www.marketscreener.com
A 10% owner's firm buys IRIDEX (IRIX) shares in 30 open-market transactions. - Stock Titan
A 10% owner reports 30 previously unreported IRIDEX (IRIX) purchases by Xinpo. - Stock Titan
Iridex Corporation Completes Relocation of Manufacturing Facility to San Jose, California - marketscreener.com
After delivering or withholding 23,917 shares, IRIDEX (IRIX) CEO holds 444,867 shares directly. - Stock Titan
Iridex Completes Relocation of Manufacturing Facility to San Jose, California - Yahoo Finance
Iridex Corp (IRIX-Q) Stock Price and News - theglobeandmail.com
IRIDEX (IRIX) CFO buys 7,900 more shares - stocktitan.net
IRIDEX (IRIX) CFO adds 2,354 shares in open-market buy - stocktitan.net
CFO now holds 175,052 shares after Iridex Corp (IRIX) stock buy - stocktitan.net
IRIDEX Received Notice of Noncompliance - tradingview.com
IRIDEX (NASDAQ:IRIX): What Is Driving Penny Stock Attention? - Kalkine Media
IRIDEX (NASDAQ:IRIX): Is Clinical Demand Building Momentum? - kalkinemedia.com
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15% - Yahoo Finance
IRIDEX (IRIX) CFO adds 6,668 shares in open-market buys - Stock Titan
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 - GuruFocus
IRIX Looks 45.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com South Africa
IRIDEX Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Is IRIDEX Corp (IRIX) Positioned for Growth After Q2 Earnings Mi - GuruFocus
IRIDEX Q2 Revenue Falls 7% as Retina Weakness Offsets Glaucoma Growth - minichart.com.sg
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Canada
Full Transcript: Iridex Q2 2026 Earnings Call - Benzinga
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Australia
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com UK
IRIDEX Corp reports results for the quarter ended June 30Earnings Summary - TradingView
IRIDEX CORP Q2 2026: Revenue $12.6M, EPS $(0.07) — 10-Q Summary - TradingView
IRIDEX (IRIX) glaucoma sales rise as retina revenue falls - Stock Titan
IRIDEX earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iridex Reports Q2 2026 Revenue $12.6M, Net Loss $1.3M; Cyclo G6 Probe Growth Boosts Glaucoma Sales - TradingView
Iridex falls short on Q2 revenue and earnings expectations By Investing.com - Investing.com Australia
Iridex falls short on Q2 revenue and earnings expectations By Investing.com - Investing.com Canada
Iridex falls short on Q2 revenue and earnings expectations - Investing.com
IRIDEX ($IRIX) Releases Q2 2026 Earnings | IRIX Stock News - Quiver Quantitative
Iridex Latest Results: FY26 sales guidance affirmed at $51M-$53M, below est - scanx.trade
Iridex Q2 revenue misses estimate as loss widens to $0.07 - scanx.trade
Iridex: Q2 Earnings Snapshot - marketscreener.com
Iridex Corp Stock (IRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iridex Corp Stock (IRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Sep 16 '26 |
Buy |
0.63 |
7,900 |
4,977 |
185,306 |
| Dizon Romeo R | Chief Financial Officer |
Sep 14 '26 |
Buy |
0.65 |
2,354 |
1,530 |
177,406 |
| Dizon Romeo R | Chief Financial Officer |
Sep 10 '26 |
Buy |
0.68 |
5,100 |
3,468 |
175,052 |
| Dizon Romeo R | Chief Financial Officer |
Aug 24 '26 |
Buy |
0.75 |
6,668 |
4,999 |
169,952 |
| Dizon Romeo R | Chief Financial Officer |
Jun 12 '26 |
Buy |
1.14 |
975 |
1,110 |
135,975 |
| Dizon Romeo R | Chief Financial Officer |
Jun 11 '26 |
Buy |
1.14 |
1,675 |
1,909 |
135,000 |
| Dizon Romeo R | Chief Financial Officer |
Jun 08 '26 |
Buy |
1.12 |
2,400 |
2,688 |
133,325 |
| Dizon Romeo R | Chief Financial Officer |
Jun 05 '26 |
Buy |
1.15 |
2,521 |
2,899 |
130,925 |
| Dizon Romeo R | Chief Financial Officer |
Jun 03 '26 |
Buy |
1.17 |
2,400 |
2,808 |
128,404 |
| Dizon Romeo R | Chief Financial Officer |
May 26 '26 |
Buy |
1.00 |
5,004 |
5,004 |
126,004 |
3.06%
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):